Market Research Logo

Biosimilars Market, Europe, Forecast to 2025

Biosimilars Market, Europe, Forecast to 2025

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU.

Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5–7 years.

The study analyzes the supply market dynamics and forecasts future revenues for key biosimilars in the European region. It also identifies the six key issues to determine the strategic imperatives for success and growth in this market. Moreover, it includes an in-depth analysis of the biosimilar value chain and the payer and regulatory environment. By assessing the impact of trends, disruptive technologies, and new business models, the study arrives at key visioning scenarios for the biosimilars market in Europe. These will help market participants make strategic decisions, stay ahead of their competitors, and gain a significant share in the market. The study also sheds light on strategic partnerships among companies in the European biosimilars market.

Highlights of the report include:
• Growth Opportunities and Challenges
• Supply Market Dynamics
• Payer and Regulatory Environment Analysis
• Strategic Imperatives for Success and Growth–The Six Tactical Issues
• Visioning Scenarios for the Biosimilars Market
• Business Model Essentials
• A Macro Overview of the Biosimilars Market


  • Executive Dashboard
    • Pharma/Biotech Market-Emerging Trends
    • Market Snapshot-Biosimilars
      • Table Total Biosimilar Market: Key Biologic Patent Losses, Europe, 2004-2021
    • Revenue Forecast
      • Table Total Biosimilars Market: Revenue Forecast, Global, 2015-2025
    • Revenue Forecast by Region
      • Table Total Biosimilars Market: Revenue Forecast by Region, Global, 2015-2025
    • Percent Revenue Forecast by Region
      • Table Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015-2025
    • Biosimilars Ecosystem-Industry Convergence Map
    • Ecosystem Partnerships-An Opportunity
    • Changing Market Scenario-Disruptive Trends
    • Patent Expiries
      • Table Total Biosimilars Market: Major Patent Expiries: Europe and US, 2000-2030
    • Key Regions
    • Technology Innovation
    • Global Biosimilars Industry-Six Big Market Themes
  • Growth Environment
    • Market Overview
    • Key Challenges in the Biosimilars Market
    • Market Segmentation by Therapeutic Areas
    • Trends in the Global Biosimilars Market
    • Global Biosimilar Patenting Trends
    • Biosimilars Adoption-Key Determinants
    • Physician Adoption of Biosimilars-Major Determinants
  • Drivers and Restraints-Total European Biosimilars Market
    • Drivers and Restraints
    • Impact Mapping of Drivers and Restraints
  • Growth Opportunity and Market Forecast-Total European Biosimilars Market
    • Percent Revenue Forecast by Region
      • Table Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015-2025
    • Revenue Forecast
      • Table Total Biosimilars Market: Revenue Forecast, Europe, 2015-2025
    • Revenue Forecast by Molecule Type
      • Table Total Biosimilars Market: Revenue Forecast by Molecule Type, Europe, 2015-2025
    • Snapshot-EU Biosimilars Market
    • Opportunity Heat Map-European Biosimilars Market
  • Growth Opportunity and Market Forecast of Key Biosimilars-Oncology
    • Top-selling Biotech Drugs
      • Table Oncology Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
    • Growth Opportunities in Oncology
    • Trastuzumab Biosimilars Adoption Rate
      • Table Oncology Therapeutic Segment: Trastuzumab Biosimilars Adoption Rate, Europe, 2014-2025
    • Trastuzumab Biosimilars Patient Population
      • Table Oncology Therapeutic Segment: Trastuzumab Patient Population, Europe, 2014 and 2025
    • Trastuzumab Biosimilars-Patient Population Forecast
      • Table Oncology Therapeutic Segment: Trastuzumab Patient Population Forecast, Europe, 2015-2025
    • Trastuzumab Biosimilars-Pricing and Discounts
      • Table Oncology Therapeutic Segment: Herceptin(R) Price and Biosimilars Discount, Europe, 2014-2025
    • Trastuzumab Biosimilars-Revenue Forecast
      • Table Oncology Therapeutic Segment: Trastuzumab Revenue Forecast, Europe, 2015-2025
    • Bevacizumab Biosimilars-Adoption Rate
      • Table Oncology Therapeutic Segment: Bevacizumab Biosimilars Adoption Rate, Europe, 2014-2025
    • Bevacizumab Biosimilars-Patient Population
      • Table Oncology Therapeutic Segment: Bevacizumab Patient Population, Europe, 2014 and 2025
    • Bevacizumab Biosimilars-Patient Population Forecast
      • Table Oncology Therapeutic Segment: Bevacizumab Biosimilars Patient Population Forecast, Europe, 2015-2025
    • Bevacizumab Biosimilars-Pricing and Discounts
      • Table Oncology Therapeutic Segment: Avastin(R) Price and Biosimilars Discount, Europe, 2014-2025
    • Bevacizumab Biosimilars-Revenue Forecast
      • Table Oncology Therapeutic Segment: Bevacizumab Biosimilars Revenue Forecast, Europe, 2015-2025
  • Growth Opportunity and Market Forecast of Key Biosimilars-Diabetes
    • Top-selling Biotech Drugs
      • Table Diabetes Therapeutic Segment: Growth Opportunities, Europe, 2016-2025
    • Growth Opportunities in Diabetes
    • Insulin Glargine Biosimilars-Adoption Rate
      • Table Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Adoption Rate, Europe, 2014-2025
    • Insulin Glargine Biosimilars-Patient Population
      • Table Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population, Europe, 2014 and 2025
    • Insulin Glargine Biosimilars-Patient Population Forecast
      • Table Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population Forecast, Europe, 2015-2025
    • Insulin Glargine Biosimilars-Pricing and Discounts
      • Table Diabetes Therapeutic Segment: Lantus Price and Biosimilars Discount, Europe, 2014-2025
    • Insulin Glargine Biosimilars-Revenue Forecast
      • Table Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Revenue Forecast, Europe, 2015-2025
  • Growth Opportunity and Market Forecast of Key Biosimilars-Rheumatoid Arthritis
    • Top-selling Biotech drugs
      • Table Rheumatoid Arthritis Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
    • Growth Opportunities in Rheumatoid Arthritis
    • Etanercept Biosimilars-Adoption Rate
      • Table Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Adoption Rate, Europe, 2014-2025
    • Etanercept Biosimilars-Patient Population
      • Table Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilar Patient Population, Europe, 2014 and 2025
    • Etanercept Biosimilars-Patient Population Forecast
      • Table Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Patient Population Forecast, Europe, 2015-2025
    • Etanercept Biosimilars-Pricing and Discounts
      • Table Rheumatoid Arthritis Therapeutic Segment: Enbrel(R) Price and Biosimilars Discount, Europe, 2014-2025
    • Etanercept Biosimilars-Revenue Forecast
      • Table Rheumatoid Arthritis Therapeutic Segment: Etanercept Revenue Forecast, Europe, 2015-2025
    • Infliximab Biosimilars-Adoption Rate
      • Table Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Adoption Rate, Europe, 2014-2025
    • Infliximab Biosimilars-Patient Population
      • Table Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population, Europe, 2014 and 2025
    • Infliximab Biosimilars-Patient Population Forecast
      • Table Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population Forecast, Europe, 2015-2025
    • Infliximab Biosimilars-Pricing and Discounts
      • Table Rheumatoid Arthritis Therapeutic Segment: Remicade(R) Price and Biosimilars Discount, Europe, 2014-2025
    • Infliximab Biosimilars-Revenue Forecast
      • Table Rheumatoid Arthritis Therapeutic Segment: Infliximab Revenue Forecast, Europe, 2015-2025
    • Adalimumab Biosimilars-Adoption Rate
      • Table Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Adoption Rate, Europe, 2014-2025
    • Adalimumab Biosimilars-Patient Population
      • Table Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population, Europe, 2014 and 2025
    • Adalimumab Biosimilars-Patient Population Forecast
      • Table Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population Forecast, Europe, 2015-2025
    • Adalimumab Biosimilars-Pricing and Discounts
      • Table Rheumatoid Arthritis Therapeutic Segment: Humira(R) Price and Biosimilars Discount, Europe, 2014-2025
    • Adalimumab Biosimilars-Revenue Forecast
      • Table Rheumatoid Arthritis Therapeutic Segment: Adalimumab Revenue Forecast, Europe, 2015-2025
  • Market Challenges-Biosimilars
    • Challenge 1-Interchangeability
    • Challenge 2-Innovation in Biologics and Biobetters
  • Supply Market Dynamics-Europe
    • Future of Biosimilars in Europe
    • Competitive Landscape Analysis
    • Market Analysis-Europe
    • Regional Hot Spots-EU5 Perspective
    • Country Attractiveness
    • Biosimilar Uptake in Scandinavia-A Case Study
    • Key Companies to Watch
    • Merger, Acquisition, and Partnership Assessment
      • Table Total Biosimilars Market: Key M&A Assessment, Europe, 2015-16
    • Biosimilars under Review by EMA
      • Table Total Biosimilars Market: Key Biosimilars under Review, Europe, 2015-16
  • Strategic Imperatives and Critical Success Factors for Europe
    • Payer Environment
    • Regulatory Environment
    • Impact of Policies-An EU5 Perspective
    • Development Process and Technical Requirements
    • Business Models to Mitigate Concerns over Cost
    • Strategic Imperatives for Success and Growth
    • Strategies for Innovators-Case Studies
    • Strategies for Foreign Participants in the EU
  • Conclusion
    • Visioning Scenarios for the Biosimilars Market
    • Business Model Essentials
    • 5 Competitive Keys for Success in the Biosimilars Market
  • Appendix
    • Global Regulatory Landscape
    • Impact of Regulations in the Biosimilars Market
  • Introduction to Biosimilars
    • Biosimilars are Not Generics-A Comparison of Generics, Biologics, and Biosimilars
    • Biologics and Biosimilars-Differences in Manufacturing Processes
    • Development Process and Technical Requirements for Biosimilars
    • Timeline for the Development of a Biosimilar Medicine
    • Value Chain Analysis-Development of a Biosimilar
    • Market Evolution of Biosimilars, 2015
    • Comparing the Players-Big Pharma (Innovators), Biotech Firms, and Generic Manufactures
    • List of Biosimilars Approved in Europe
      • Table Total Biosimilars Market: List of Biosimilars Approved, Europe, 2016
    • List of Biosimilars under Review by EMA
      • Table Total Biosimilars Market: List of Biosimilars under Review by EMA, Europe, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report